Atpenin A5 is known as a potent complex II inhibitor 70 , thus affecting the redox chain at the mitochondrial membrane and overall energy metabolism
Common Side Effects (Both Medications): Gastrointestinal Side Effects (Most Common): These typically occur when starting treatment or increasing doses, and often improve over time: Nausea: Most frequent side effect for both medications Semaglutide: 44% of participants in clinical trials Tirzepatide: 30-37% depending on dose Usually mild to moderate Most common in weeks 1-8, improves with continued use Diarrhea: Semaglutide: 30% of participants Tirzepatide: 19-23% depending on dose Often resolves within a few weeks Staying hydrated helps manage symptoms Constipation: Semaglutide: 24% of participants Tirzepatide: 10-17% depending on dose Can alternate with diarrhea Fiber and hydration help Vomiting: Semaglutide: 24% of participants Tirzepatide: 9-17% depending on dose More common at higher doses May require dose reduction Abdominal Pain: Semaglutide: 20% of participants Tirzepatide: 8-11% depending on dose Usually mild, related to slower stomach emptying Other Common Side Effects: Appetite Changes: Decreased appetite (desired effect) Food aversions or taste changes Reduced interest in previously enjoyed foods Early satiety (feeling full quickly) Fatigue: Semaglutide: 11% of participants Tirzepatide: Similar rates Often related to reduced calorie intake May improve as body adjusts Injection Site Reactions: Mild redness, swelling, or itching at injection site Usually resolves within a few days Rotating injection sites helps minimize Headache: Occurs in 10-14% of participants with both medications Usually mild and temporary Often related to dehydration Side Effect Comparison: Why Tirzepatide May Have Fewer GI Side Effects: Despite being more potent, tirzepatide appears to cause slightly less nausea and GI distress
2.19.20 15mins said: Looks ok
The induction of diabetes and CKD using STZ and adenine, respectively, in the experimental animals resulted in significant hyperglycemia, weight loss, polyuria, impaired renal function and structure, and increased oxidative stress accompanied by a compromised antioxidant defense system and dysregulated inflammatory markers
Avoid Stacking With Insulin Unless Supervised Stacking IGF-1 with insulin dramatically increases hypoglycemia risk and should only be done under professional guidance
[11] Increased demand for healthier options such as fruits and vegetables (55%), protein shakes, and meal replacements is also seeing growth as they align with the dietary needs of GLP-1 users
